Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome

Authors: Chihrin, Stephen; Loutfy, Mona R

Source: Expert Review of Anti-Infective Therapy, Volume 3, Number 2, April 2005 , pp. 251-262(12)

Publisher: Expert Reviews

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

In 2003, an outbreak of a novel respiratory virus exploded from mainland China into an international issue, catching the world by surprise. The ensuing challenges to hospital and public health workers rose to a level never before seen in healthcare, in part due to the unknown nature of the disease, the fear of the human-to-human transmission and the significant media involvement. A new coronavirus was identified as the causative agent and named the severe acute respiratory syndrome-associated virus. A number of antiviral and anti-inflammatory treatment strategies were explored during the epidemic, with varying success. Following the epidemic, in vitro antiviral analyses of numerous compounds have been conducted. This review summarizes treatment agents assessed during and after the 2003 severe acute respiratory syndrome outbreak, with the aim of guiding future decision makers should the virus return.

Keywords: chloroquine; corticosteroids; interferon; lopinavir/ritonavir; plasma exchange; ribavirin; severe acute respiratory syndrome; treatment

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14787210.3.2.251

Affiliations: 1: University of Western Ontario, Faculty of Medicine, London, Ontario, Canada

Publication date: 2005-04-01

More about this publication?
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page